"Pharmaceutical and Biotechnology Transactions in the Current Economic Environment" (Client Presentation)

June 9, 2009

Small and mid-size pharmaceutical and biotech companies are facing a severe contraction in the availability of traditional financing sources. At the same time, major pharma and mature biotech players are looking to fill gaps in their product pipelines. In this seminar, our panelists discussed the state of the financing and M&A markets in this sector, innovative techniques for addressing current market challenges and some of the legal issues that arise in these transactions. Specific topics included:

  • Financing pharma/biotech companies in today's markets
  • Bridging the Value Gap: contingent value rights, options and other alternative transaction structures
  • Managing bankruptcy risks in M&A and licensing transactions

Kaye Scholer attorneys were joined in a panel discussion by industry insiders:

Adam Golden, Partner, Kaye Scholer LLP
Rory Greiss, Partner, Kaye Scholer LLP
Andrew Kress, Partner, Kaye Scholer LLP

Lyn Baranowski, Vatera Capital
Richard Kollender, Quaker BioVentures
Michael Margolis, Merriman Curhan Ford & Co.

Subscribe Link

Email Disclaimer